Related references
Note: Only part of the references are listed.Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (carcinoid): Results from the Phase 2 ATLANT Study
Piero Ferolla et al.
NEUROENDOCRINOLOGY (2023)
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective
Francesca Spada et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors
Jane E. Rogers et al.
NEUROENDOCRINOLOGY (2022)
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
Taymeyah Al-Toubah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Valentina Ambrosini et al.
CANCERS (2022)
Survival According to Therapy Regimen for Small Intestinal Neuroendocrine Tumors
Christine Koch et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
Jennifer Rachel Eads et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.
Nick Pavlakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).
Pamela L. Kunz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations
Hege Elvebakken et al.
NEUROENDOCRINOLOGY (2021)
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Baudin et al.
ANNALS OF ONCOLOGY (2021)
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A Real-World Data Analysis
Alberto Bongiovanni et al.
NEUROENDOCRINOLOGY (2021)
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide
Taymeyah Al-Toubah et al.
ONCOLOGIST (2021)
Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials
Claudio Ricci et al.
CANCERS (2021)
Chemotherapy in NEN: still has a role?
Paula Espinosa-Olarte et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2021)
Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis
P. Trillo Aliaga et al.
CANCER TREATMENT REVIEWS (2021)
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Manisha H. Shah et al.
Journal of the National Comprehensive Cancer Network (2021)
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naive Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial
Enrique Grande et al.
ONCOLOGIST (2021)
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis
Francesca Spada et al.
ENDOCRINE (2021)
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Louis de Mestier et al.
NEUROENDOCRINOLOGY (2020)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours
George Papaxoinis et al.
NEUROENDOCRINOLOGY (2020)
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms
Taymeyah Al-Toubah et al.
ONCOLOGIST (2020)
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study
Nicole Brighi et al.
ONCOLOGIST (2020)
Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms
Hiroaki Ono et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Hereditary Syndromes in Neuroendocrine Tumors
Mark A. Lewis
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors
Nataliya V. Uboha et al.
INVESTIGATIONAL NEW DRUGS (2020)
Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors
Alessandra Pulvirenti et al.
FRONTIERS IN MEDICINE (2020)
Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit
Giuseppe Lamberti et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms
Elettra Merola et al.
PANCREAS (2020)
Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors
Ashley L. Titan et al.
JAMA NETWORK OPEN (2020)
Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study
Nicole Brighi et al.
DIGESTIVE AND LIVER DISEASE (2019)
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
Alireza Mansouri et al.
NEURO-ONCOLOGY (2019)
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors
Mauro Cives et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors
Mauro Cives et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases
Jordan M. Cloyd et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study
Davide Campana et al.
ENDOCRINE (2018)
Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors
Laura Prakash et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2017)
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience
Guillermo Crespo et al.
FUTURE ONCOLOGY (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy
Rocio Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology Well Differentiated Versus Poorly Differentiated
Nitya Raj et al.
PANCREAS (2017)
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Bryan Oronsky et al.
NEOPLASIA (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Susumu Hijioka et al.
CLINICAL CANCER RESEARCH (2017)
Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract
Mauro Cives et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors
M. Cives et al.
ENDOCRINE-RELATED CANCER (2016)
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
J. Cros et al.
ENDOCRINE-RELATED CANCER (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Francesca Spada et al.
NEUROENDOCRINOLOGY (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors
Robert A. Ramirez et al.
ONCOLOGIST (2016)
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
Romain Coriat et al.
ONCOLOGIST (2016)
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials
Pamela L. Kunz et al.
PANCREAS (2016)
Defining the Role of Adjuvant Chemotherapy After Lobectomy for Typical Bronchopulmonary Carcinoid Tumors
Daniel P. Nussbaum et al.
ANNALS OF THORACIC SURGERY (2015)
Atypical Carcinoid Tumor of the Lung A Surveillance, Epidemiology, and End Results Database Analysis
Conor E. Steuer et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension
F. Dumont et al.
WORLD JOURNAL OF SURGERY (2015)
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
Alfredo Berruti et al.
BMC CANCER (2014)
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial
Michel Ducreux et al.
EUROPEAN JOURNAL OF CANCER (2014)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) - A phase II non-randomised trial
Emmanuel Mitry et al.
EUROPEAN JOURNAL OF CANCER (2014)
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours
Tim Meyer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids
Niccolo Daddi et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2014)
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors
Robert Lance Fine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid
Patrick M. Forde et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors
Curtis R. Chong et al.
LUNG CANCER (2014)
MGMT testing-the challenges for biomarker-based glioma treatment
Wolfgang Wick et al.
NATURE REVIEWS NEUROLOGY (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
Jennifer A. Chan et al.
CANCER (2013)
Bevacizumab Plus Temozolomide: A Novel Treatment Option for Advanced Neuroendocrine Tumors?
Anna Koumarianou et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Jennifer A. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
L. Medley et al.
BRITISH JOURNAL OF CANCER (2011)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
Hedia Brixi-Benmansour et al.
DIGESTIVE AND LIVER DISEASE (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Temozolomide: Mechanisms of Action, Repair and Resistance
Jihong Zhang et al.
Current Molecular Pharmacology (2011)
Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis
Skye C. Mayo et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
N. C. Turner et al.
BRITISH JOURNAL OF CANCER (2010)
NANETS Treatment Guidelines Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Matthew H. Kulke et al.
PANCREAS (2010)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC-FFCD 9710
Laetitia Dahan et al.
ENDOCRINE-RELATED CANCER (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?
Frederique Maire et al.
SURGERY (2009)
A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma
M. A. Mani et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Typical and atypical carcinoid tumours:: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung
Mariano Garcia-Yuste et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2007)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas
M. P. Ducreux et al.
ONCOLOGY (2006)
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
WJ Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Experience in treatment of metastatic pulmonary carcinoid tumors
D Granberg et al.
ANNALS OF ONCOLOGY (2001)
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282
RK Ramanathan et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
